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Abstract—The UBE3A gene is part of the chromosome 15q11-q13 region that is frequently deleted or duplicated,
leading to several neurodevelopmental disorders (NDD). Angelman syndrome (AS) is caused by the absence of
functional maternally derived UBE3A protein, while the paternal UBE3A gene is present but silenced speciﬁcally
in neurons. Patients with AS present with severe neurodevelopmental delay, with pronounced motor deﬁcits,
absence of speech, intellectual disability, epilepsy, and sleep problems. The pathophysiology of AS is still
unclear and a treatment is lacking. Animal models of AS recapitulate the genotypic and phenotypic features
observed in AS patients, and have been invaluable for understanding the disease process as well as identifying
apropriate drug targets. Using these AS mouse models we have learned that loss of UBE3A probably aﬀects many
areas of the brain, leading to increased neuronal excitability and a loss of synaptic spines, along with changes in
a number of distinct behaviours. Inducible AS mouse models have helped to identify the critical treatment win-
dows for the behavioral and physiological phenotypes. Additionally, AS mouse models indicate an important role
for the predominantly nuclear UBE3A isoform in generating the characteristic AS pathology. Last, but not least,
the AS mice have been crucial in guiding Ube3a gene reactivation treatments, which present a very promising
therapy to treat AS.
This article is part of a Special Issue entitled: [Animal Models].  2020 The Authors. Published by Elsevier Ltd on behalf of
IBRO. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Human neurodevelopment is a relatively long process
resulting from complex interactions between genes and
environment, with a crucial impact on the formation of
diﬀerentiated neurons, synapses and ultimately
functional neuronal networks (Silbereis et al., 2015). Dys-
function of the ubiquitin ligase gene UBE3A which is
speciﬁcally imprinted in the brain (Albrecht et al., 1997;
Rougeulle et al., 1997; Vu and Hoﬀman, 1997; Hsiao
et al., 2019) leads to two severe human neurodevelop-
mental disorders (NDDs): Angelman syndrome (AS)
caused by the deletion or dysfunction of the maternal
UBE3A allele and the 15q11.2-q13.3 duplication
(Dup15q) syndrome, resulting from the duplication of the
allele (Glessner et al., 2009; Urraca et al., 2013) and
reviewed in (Elgersma, 2015). It remains largely unclear
how UBE3A contributes to the pathophysiology of these
two diﬀerent NDDs, but the levels of UBE3A protein arehttps://doi.org/10.1016/j.neuroscience.2020.02.017
0306-4522/ 2020 The Authors. Published by Elsevier Ltd on behalf of IBRO.
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ferent disorders (Elgersma, 2015). Thus loss of UBE3A
protein in the brain leads to severe neurological and cog-
nitive deﬁcits while increased levels of UBE3A lead to aut-
ism spectrum disorders (ASD) phenotypes or increased
risk for schizophrenia (Urraca et al., 2013; Elgersma,
2015). In this review, we speciﬁcally focus on AS, and
review how AS mouse models have contributed to what
we know about UBE3A today, and guide the development
of therapies.AS AND THE IMPORTANCE OF UBE3A FOR
NEURODEVELOPMENT
AS is a severe debilitating NDD with an estimated
incidence of 1 in 20,000 (Mertz et al., 2013), caused by
the absence of functional maternally derived UBE3A pro-
tein. The developmental delay emerges around 6 months
of age and becomes gradually more apparent after
12 months (Williams et al., 2010). The developmental
milestones are not only delayed, but plateau at a develop-
mental level of 24–30 months (Williams et al., 2006). Chil-
dren with AS have strong deﬁcits of ﬁne and gross motor
skills, absence of speech, intellectual disability and abnor-
mal demeanour, occasionally resembling ASD (Williams
et al., 2006). Additionally, 80% of the patients haveons.org/licenses/by-nc-nd/4.0/).
science (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
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Bindels-de Heus et al., 2019). Currently, only symp-
tomatic treatment is available, which is predominantly
aimed at reducing seizures and improving sleep (Tan
and Bird, 2015).
Aﬀected locus in humans
The UBE3A gene encodes the prototype of a subfamily of
C-terminal HECT (Homologous to the E6-AP Carboxy
Terminus) E3 ligases (Scheﬀner et al., 1993). Ubiquitin
ligases are essential enzymes in the ubiquitin–protea-
some pathway, involved in a number of processes includ-
ing protein degradation, intracellular traﬃcking, DNA
repair and replication (Hamilton et al., 2013). The identiﬁ-
cation of UBE3A function in 1993 as a ubiquitin ligase,
originated from its role in human papilloma virus mediated
cervical cancer (Huibregtse et al., 1993a,b; Scheﬀner
et al., 1993; Talis et al., 1998). It would take another
4 years before the UBE3A gene was linked to AS
(Kishino et al., 1997; Matsuura et al., 1997; Sutcliﬀe
et al., 1997), a syndrome ﬁrst described by Harry Angel-
man in 1965 (Angelman, 1965).
The UBE3A gene is located on chromosome 15q11.2
in humans (Matsuura et al., 1997; Sutcliﬀe et al., 1997),
which is part of the 15q11-q13 region that is frequently
deleted or duplicated. Deletion of this region [del(15)
(q11-q13)] results in two distinct disorders, AS or Prader
Willi syndrome (PWS), that are cytologically indistinguish-
able from each other but give rise to distinct clinical disor-
ders (Ledbetter et al., 1981; Kaplan, 1987; Magenis et al.,
1987). The fact that some patients aﬄicted with PWS
carry 2 copies of maternal chromosome 15 whereas a
subset of individuals with AS harbour 2 paternal copies
of chromosome 15 led to the recognition of the parent-
of-origin eﬀect in PWS and AS (Nicholls et al., 1989;
Malcolm et al., 1991). The subsequent identiﬁcation of
various missense mutations and small deletions, that
directly impacted the UBE3A gene in a number of AS
patients, led to the identiﬁcation of the gene responsible
for AS (Kishino et al., 1997; Matsuura et al., 1997). Inter-
estingly, during evolution the UBE3A gene was already
present before the development of the nervous system
(Rapkins et al., 2006), but its imprinting was established
after the diversiﬁcation of marsupials and placental mam-
mals via multiple chromosomal rearrangements that
formed the domain controlling maternal expression of
UBE3A from non-imprinted regions (Rapkins et al.,
2006). The importance of UBE3A imprinting coinciding
with higher mammalian cognition remains unclear, but it
may have been important for its role in neuronal function.
Understanding how UBE3A regulates brain development
may uncover the speciﬁc pathways aﬀected by UBE3A-
associated disorders (Zhang et al., 2014).
The imprinting of UBE3A is highly unusual for two
reasons; ﬁrstly, it is speciﬁcally imprinted in most
neurons of the brain (Albrecht et al., 1997; Rougeulle
et al., 1997; Vu and Hoﬀman, 1997; Runte et al., 2001;
Varon et al., 2004; Jones et al., 2016), and secondly it
actually falls just outside the methylated region that is
responsible for the parent-of–origin imprinting. As shown
in Fig. 1, a number of genes around the Prader WilliPlease cite this article in press as: Rotaru DC et al. Angelman Syndrome: From Mouse Models to Therapy. Neuimprinting center (PWS-IC) are transcribed solely from
the paternal locus, which includes the large UBE3A-ATS
(SNHG14) transcript. Initiation of UBE3A-ATS transcrip-
tion starts at the ﬁrst exon of SNRPN which overlaps with
the PWS-IC, a stretch of CpG islands methylated early
during female gametogenesis as a consequence of AS
imprinting center (AS-IC) transcriptional activity, inhibiting
SNRPN transcription (Smith et al., 2011). The paternal
PWS-IC counterpart is left unmodiﬁed and allows tran-
scription initiation forming the UBE3A-ATS transcript that
stretches beyond SNRPN to include the SNORD116 clus-
ter of RNAs until the IPW where transcription ceases.
Speciﬁcally in mature neurons of the brain, a shift in chro-
matin structure occurs whereby the UBE3A-ATS tran-
script is elongated beyond the IPW to now include the
SNORD115 RNA cluster (Hsiao et al., 2019) after which
the UBE3A-ATS transcriptional complex is believed to
clash with that originating from the UBE3A promoter,
leading to the cessation of both transcripts around exon
4/5 of UBE3A (Meng et al., 2012, 2013) (Fig. 1). This phe-
nomenon, referred to as the collision model, is believed to
form the basis of the paternal UBE3A transcriptional
silencing encountered in mature neurons. Experimental
evidence for this model was provided by engineering a
mouse model in which transcription of the Ube3a-ATS
was forced to stop before it reached the Ube3a gene,
which resulted in bi-allelic Ube3a expression (Meng
et al., 2013).
THE AS ANIMAL MODEL
To identify targeted treatments and ensure the successful
translation of these therapies to clinical trials, mouse
models are needed that have high construct (similarity
at genotypic level) and face validity (similarity at
phenotypic level), as well as robust behavioural
phenotypes (Katz et al., 2012; Sonzogni et al., 2018).
Construct validity
There is a high degree of genetic similarity shared
between the locus aﬀected in human individuals with AS
(15q11-q13) and the syntenic region on mouse
chromosome 7 (Albrecht et al., 1997) (Fig. 1) with the
exception of the orientation of the region ﬂanked on
human chromosome 15 by BP2 and BP3, which in mice
is inverted. Both mouse and human loci contain the same
genes and undergo parent-of-origin speciﬁc imprinting,
including the Ube3a-ATS mediated silencing of the pater-
nal Ube3a allele (Nicholls and Knepper, 2001; Lalande
and Calciano, 2007). For these reasons, the construct
validity of mouse models for AS is potentially very high.
Mutation spectra in AS individuals. Due to the mono-
allelic nature of UBE3A transcription in neurons, any
maternal mutation causing a non-functional UBE3A
protein will result in a neuronal UBE3A knockout and
hence in AS. Although all AS patients have a loss of
functional UBE3A protein, the genetic lesions can be
variable. The majority of AS individuals (75%) carry a
large deletion within the maternally inherited
chromosome 15 that encompasses the UBE3A generoscience (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
Fig. 1. Mouse models of AS. A schematic representation of human chromosome 15q11.2-q13 region. (A) Expressed (blue and green) and silenced
(grey) genes on both the maternal and paternal chromosomes are indicated. (B) Frequently used AS mouse-models showing the mutations applied.
Note that the direction of transcription of Ube3a is towards the centromere. Crosses on exons indicate their deletion and crosses on arrows indicate
the loss of an initiating ATG codon. Red hexagons: transcriptional stop. Red exon: contains a stop codon. Red triangles: loxP site. YFP: in frame
fusion of YFP at 30 end of Ube3a. BP: breakpoint. PWS-IC: Prader Willi imprinting center. AS-IC: The ﬁlled circle represents the methylated AS-IC
allele. Angelman syndrome imprinting center. Cited references: 1) Jiang et al. (1998); 2) Wang et al. (2017); 3) Dindot et al. (2008); 4) Jiang et al.
(2010); 5) Avagliano Trezza et al. (2019); 6) Judson et al. (2016); 7) Silva-Santos et al. (2015).
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including GABRB3, GABRA5, GABRG3, encoding
gamma-aminobutyric acid type A (GABAA) receptor
subunits (Gentile et al., 2010; Buiting et al., 2016)
(Fig. 1A). The relatively high frequency of deletions in this
area is due to the presence of 2 centromeric (BP1 and
BP2) and 4 telomeric (BP3, BP4, BP4a and BP5) break-
points ﬂanking the 15q11-13q locus which are intra-
chromosomal low-copy repeats (LCR) that rearrange
and result in large deletions/duplications ranging from 5
to 10 Mb in size. The majority of deletions occur between
BP1 and BP3 (40% of deletions) and between BP2 and
BP3 (60% of deletions) (Amos-Landgraf et al., 1999;
Christian et al., 1999; Sahoo et al., 2007). The remaining
mutations leading to AS include imprinting defects aﬀect-
ing the AS-IC (3%), paternal uniparental disomy of chro-
mosome 15 (1–2%) and mutations speciﬁcally aﬀecting
the UBE3A gene (5–10%) (Buiting et al., 2016).Please cite this article in press as: Rotaru DC et al. Angelman Syndrome: From Mouse Models to Therapy. NeuroThere are a number of AS mouse models available to
researchers in the ﬁeld (reviewed in (Mabb et al., 2011;
Jana, 2012)) and updated in Fig. 1B). Arguably the ﬁrst
AS mouse model consisted of a partial paternal duplica-
tion of chromosome 7 encompassing the Ube3a locus,
and exhibited characteristic features of AS, such as
abnormal EEG (Cattanach et al., 1992, 1997). However,
besides being diﬃcult to obtain, the deletion in these mice
also included genes that are unaﬀected in human patients
(Cattanach et al., 1992). By far, the most commonly used
mouse model to date in AS research, is the one gener-
ated by the Beaudet lab in 1998 (Ube3atm1Alb; (Jiang
et al., 1998). In this mouse model, exon 5 (numbering
based on the long Ube3a mouse isoform 2) was deleted
resulting in an out of frame mutation (Jiang et al., 1998).
This mouse model was subsequently used extensively
by other labs to investigate changes in behaviour (Jiang
et al., 1998; Miura et al., 2002; Allensworth et al., 2011;science (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
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tion (Kaphzan et al., 2011; Egawa et al., 2012; Wallace
et al., 2012) and to test treatment strategies (van
Woerden et al., 2007; Egawa et al., 2012; Kaphzan
et al., 2013; Sonzogni et al., 2018). The mouse, designed
on the premise that loss of UBE3A is the common denom-
inator in all AS patients, has proven to have an excellent
construct validity in terms of brain speciﬁc imprinting,
showing a clear parent-of-origin eﬀect and a lack of
UBE3A protein in neurons derived from maternally inher-
ited mutant alleles (Jiang et al., 1998; Judson et al.,
2014). These aspects are mirrored in additional mouse
models that also directly target the Ube3a gene including
the deletion of the C-terminal tail (Miura et al., 2002),
insertion of a premature stop (PTC) (Wang et al., 2017)
and two conditional AS models either with a ﬂoxed exon
7 (Judson et al., 2016) or a conditional transcriptional stop
cassette in intron 5 (Floxed-STOP) (Silva-Santos et al.,
2015) (Fig. 1B).
As stated earlier, only about 5–10% of individuals with
AS harbour mutations in UBE3A itself. The largest portion
of aﬀected individuals carry a large deletion which
encompasses a number of ﬂanking genes, leading to a
more severe phenotype in individuals with AS (Sahoo
et al., 2007; Gentile et al., 2010; Bindels-de Heus et al.,
2019). For example, new evidence suggests that contri-
bution of non-UBE3A neuronal pathophysiology involving
the GABRB3-GABRA5-GABRG3 gene cluster causes
abnormal theta and beta EEG oscillations that may under-
lie the more severe clinical phenotype in patients with AS
(Frohlich et al., 2019). Loss of the GABAA receptor cluster
is partially modelled by a mouse model with a 1.6 Mb
deletion encompassing the Ube3a gene and the upstream
Atp10a and Gabrb3 genes (Fig. 1B), but does not include
the genes ﬂanked by BP1 and BP2 (Jiang et al., 2010).
The eﬀect of hemizygosity of the BP1/BP2 ﬂanked genes
NIPA-1, NIPA-2, CYF1P1, and GCP5 in Class 1 (between
BP1 and BP2) vs Class 2 (between BP2 and BP3) dele-
tions, however, remains unresolved with some studies
claiming no diﬀerence between the two classes of dele-
tions in terms of symptom severity (Mertz et al., 2014)
and others ﬁnding a diﬀerence (Sahoo et al., 2006,
2007; Valente et al., 2013). Interestingly, a potentially
useful deletion mouse model for AS did exist, encom-
passing all genes between BP1 and BP3 (see Fig. 1A)
but unfortunately no behavioural data is available
(Gabriel et al., 1999). Finally, imprinting defects have
recently been modelled in a mouse with a transcriptional
stop cassette inserted upstream of the PWS-IC, resulting
in a AS-like imprinting defect when the stop cassette is
maternally inherited (Lewis et al., 2019).
Face validity
The face validity of a mouse model is determined by how
closely it recapitulates the patient clinical features. The
commonly used AS mouse model developed by
Beaudet’s lab (Ube3a exon 5 deletion; Fig. 1), captures
many neurological key features of the disorder (e.g.
epilepsy, motor deﬁcits, abnormal EEG), as well as
some of the behavioural abnormalities (e.g. abnormal
sleep patterns, increased anxiety, repetitive behaviourPlease cite this article in press as: Rotaru DC et al. Angelman Syndrome: From Mouse Models to Therapy. Neu(Jiang et al., 1998; Miura et al., 2002; Allensworth et al.,
2011; Huang et al., 2013; Born et al., 2017; Sonzogni
et al., 2018). Below we brieﬂy reviewed the face validity
(or lack of it), by the diﬀerent behavioral domains (Fig. 2).
Cognitive dysfunction. Cognitive function is severely
aﬀected in individuals with AS, with psychometric testing
suggesting the upper developmental age is between 24
and 30-months (Andersen et al., 2001; Peters et al.,
2004).
Deﬁcits in cognitive function of AS mouse models
(mostly Ube3atm1Alb), have been shown several times
using fear conditioning and water maze learning
paradigms (Jiang et al., 1998; van Woerden et al.,
2007; Huang et al., 2013). But surprisingly, the learning
deﬁcits observed on these tasks tend to be mild, have
not yielded consistent results across labs, and should
therefore be interpreted with care (Jiang et al., 1998;
Born et al., 2017) as discussed by (Sonzogni et al.,
2018)). Interestingly, a recent study showed that beha-
vioural extension is changed in the AS model mice
(Sidorov et al., 2018). This speciﬁc operant behavioural
paradigm is an active learning process (De Carvalho
Myskiw et al., 2015) known to engage prefrontal circuits
such as the infralimbic (IL) medial prefrontal cortex
(mPFC) in rodents (Peters et al., 2009). The prefrontal
cortex is involved in cognitive function (Miller and
Cohen, 2001), and dysfunction in prefrontal circuits likely
contributes to cognitive impairments in NDDs such as AS
(Yuan and Raz, 2014). In future studies, this new beha-
vioural phenotype may be a more suitable test for assess-
ing the cognitive impairments in AS mice. More so, the
behavioural tests that involve the higher-order circuits
involved in cognition may become especially important
in the preclinical assessment of treatment eﬃcacy,
because such circuits may have protracted critical periods
for intervention (Rotaru et al., 2018).
Motor deﬁcits
Patients with AS have severe motor dysfunction that ﬁrst
manifests around 6 months of age as hyperkinetic
movements of the trunk and limbs, jitteriness or
trembling (Fryburg et al., 1991; Williams et al., 2006).
Older children have orthopaedic and movement diﬃcul-
ties, gait disturbance, coordination and lack of complex
motor skills development. Overall, there is a severe delay
in motor milestones such as sitting, which usually occurs
after 12 months, and walking, which is often delayed until
age 3–5 years (Zori et al., 1992; Buntinx et al., 1995).
Eventually walking is either stiﬀ or extremely shaky and
jerky and about 10% of the children never achieve walking
(Clayton-Smith and Laan, 2003; Beckung et al., 2004;
Bindels-de Heus et al., 2019). Voluntary movements are
often uncoordinated and children are unable to reach for
objects or feed themselves (Clayton-Smith, 1993;
Beckung et al., 2004; Grieco et al., 2018).
Several behavioural tasks have been used to assess
motor dysfunction in AS mouse models, including the
hind-paw footprint analysis, bar crossing ability, wire
hanging, paw position in the tail suspension test (Jiang
et al., 1998; Heck et al., 2008), and performance on anroscience (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
Fig. 2. Face validity of the AS mouse model. Summary of the major neurological deﬁcits described in patients with AS (left) versus similar
phenotypes observed in AS mice after speciﬁc behavioral tasks (right). The strong phenotypes observed in AS mice are made bold.
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Silva-Santos et al., 2015; Born et al., 2017; Sonzogni
et al., 2018; Avagliano Trezza et al., 2019). The latter task
is the most commonly used assay and yields a robust
phenotype which is consistent across labs, and mouse
models (Jiang et al., 1998; Huang et al., 2013; Silva-
Santos et al., 2015; Born et al., 2017; Sonzogni et al.,
2018).Please cite this article in press as: Rotaru DC et al. Angelman Syndrome: From Mouse Models to Therapy. NeuroAbsence of speech. Most individuals with AS lack
speech. Only few individuals can use several words but
they are rarely able to make phrases (Trillingsgaard and
Østergaard, 2004). Ultimately, communication is
achieved by using gestures (Clayton-Smith, 1993), or
more recently by communication devices. This distinct
feature of AS is not easily recapitulated in the mouse
model. Although it is common for vertebrates to usescience (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
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complexity of such behaviours varies extensively among
species (Petkov and Jarvis, 2012). Most animals commu-
nicate via innate vocalization, and only primates and a few
bird species through imitation, which is the main way
humans develop language skills (Konopka and Roberts,
2016). Mice are vocal non-learners but they also have
rudimentary cortical-striatal circuits similar to those that
control production of learned vocalizations in humans
and songbirds, and these circuits activate when they
vocalize (Arriaga et al., 2012). Ultrasonic vocalization
(USV) was investigated in AS mice with a deletion which
encompassed the Ube3a, Atp10a and Gabrb3 genes
(Jiang et al., 2010). Notably, USV calls were increased
in these AS mice. Nevertheless, it should be mentioned
that the investigators used newborn pups and their USVs
may reﬂect an innate behavior at this age. Hence, the
data may reﬂect a dysfunction of an innate behavior
rather than provide insight into the vocal learning and
speech acquisition deﬁcits observed in individuals with
AS.Behavioural dysfunction. There is variability in
adaptive behaviour in patients with AS and a substantial
subset of children with AS qualify for a comorbid
diagnosis of autism, independent of the severity of their
cognitive and adaptive behaviour functioning
(Steﬀenburg et al., 1996; Trillingsgaard and Østergaard,
2004; Peters et al., 2012). Children with AS appear hyper-
active, with short attention span (Walz, 2007). With age,
anxiety becomes signiﬁcantly stronger manifesting as
increased ﬁts and self-harm, cyclic vomiting, tics, or tre-
mors (Thibert et al., 2013; Giroud et al., 2015; Larson
et al., 2015; Prasad et al., 2018). To model at least part
of these behavioural dysfunctions, a series of behavioural
tests are now used to test AS mice (Sonzogni et al.,
2018).
Open ﬁeld assays (Prut and Belzung, 2003;
Seibenhener and Wooten, 2015) and the elevated plus
maze tests (Pellow et al., 1985; Walf and Frye, 2007)
have been extensively used to test the levels of anxiety
in rodents. These tests are rapid assessments of well-
deﬁned anxiety-mediated fear or ﬂight responses to speci-
ﬁc stimuli (Prut and Belzung, 2003; Seibenhener and
Wooten, 2015). Rodents for example, show strong aver-
sion when placed in open, bright, and novel environments
(Choleris et al., 2001). AS mice show stronger anxiety
than their wild type controls when placed in the open ﬁeld
maze (Huang et al., 2013; Silva-Santos et al., 2015; Born
et al., 2017; Sonzogni et al., 2018). Although this pheno-
type has been replicated across diﬀerent laboratories and
diﬀerent AS mouse lines, this test was shown to have less
statistical power compared to other tests that look at
behavioural dysfunction in AS mice (Sonzogni et al.,
2018).
The marble burying paradigm assesses rodent
behaviour related to natural digging and burrowing
behaviour (Gyertya´n, 1995; Thomas et al., 2009). Digging
and building burrows serves diﬀerent purposes in the wild,
including food storage, safety, nesting, thermoregulation
(Bouchard and Lynch, 1989). Often, this task showsPlease cite this article in press as: Rotaru DC et al. Angelman Syndrome: From Mouse Models to Therapy. Neurepetitive digging and burrowing (Sherwin et al., 2004;
Thomas et al., 2009) which may have similarity to the
repetitive behaviour that forms the core phenotype of
ASD. AS mouse models consistently show changes in
this behaviour (Meng et al., 2013; Silva-Santos et al.,
2015; Born et al., 2017; Sonzogni et al., 2018). However,
whereas many mouse models for ASD show increased
burying behaviour, AS mice actually show reduced bury-
ing behaviour.
Nest building is another animal behaviour serving
diverse functions, such as conservation of heat but also
for reproduction and shelter (Hansell, 2005; Deacon,
2006; Jirkof, 2014; Baden, 2019). AS mice show a
reduced capacity for nest building (Silva-Santos et al.,
2015; Sonzogni et al., 2018), but the precise translational
value of this observation is unclear as it is unknown which
brain areas are underlying this deﬁcit.
It is notable that impaired rotarod performance,
reduced open ﬁeld activity, reduced marble burying
behaviour and reduced nest building behaviour could
theoretically all be a direct result of impaired motor
function. However, this appears not to be the case.
Restoring Ube3a gene expression in 3-week old AS
mice fully restores rotarod impairments but does not
rescue any of the other tasks including reduced open
ﬁeld activity, reduced marble burying behaviour and
reduced nest building behaviour (Silva-Santos et al.,
2015).Seizure susceptibility. Seizures, including myoclonic,
atypical absence, generalized tonic–clonic, and atonic
types, usually start between 1 and 3 years (Boyd et al.,
1988; Rubin et al., 1997; Valente et al., 2006; Pelc
et al., 2008; Thibert et al., 2009). Seizures are one of
the few AS phenotypes for which there is a treatment,
although eﬃcacy of anticonvulsants is sometimes poor
(Thibert et al., 2009; Shaaya et al., 2016)
Although spontaneous seizures have not been
reported for AS mice, it is important to note that most
research on AS models has predominantly made use of
animals in a C57BL/6 background, typically a non-
seizure permissive mouse strain. Moreover, the use of
more seizure permissive strains in combination with
chronic EEG monitoring may enable the identiﬁcation of
seizures that are harder to detect by observation only.
But even though spontaneous seizures have not been
reported, AS mice have a clear increase of seizure
susceptibility, either upon audiogenic stimulation or
frequent stimulation (kindling) (Jiang et al., 1998; Born
et al., 2017). Audiogenic seizures are among the most
powerful tests to investigate seizure susceptibility in AS
mice, although this phenotype is highly background speci-
ﬁc (Jiang et al., 1998; van Woerden et al., 2007; Silva-
Santos et al., 2015; Judson et al., 2016; Born et al.,
2017; Sonzogni et al., 2018). This phenotype has been
demonstrated in four independently derived lines raised
in the 129S2 background: the commonly used exon 5
deletion line, the Floxed-STOP line, and the recently gen-
erated PTC line (see Fig. 1). Audiogenic seizures can be
prevented with anti-epileptic drugs such as valproate,
clonazepam, levetiracetam (Silva-Santos et al., 2015;roscience (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
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in AS mice induced with the ﬂurothyl GABAAR antagonist,
can be ameliorated with cannabidiol (Judson et al., 2016;
Gu et al., 2019a,b).Electroencephalographic (EEG) abnormali-
ties. Patients with AS have speciﬁc EEG abnormalities
which often precede clinical features and help support
the AS diagnosis in patients without a genetic
conﬁrmation (Laan et al., 1997; Valente et al., 2006).
The typical EEG pattern includes one or more of the fol-
lowing features: large amplitude of rhythmic delta activity
especially in the frontal regions, and persistent rhythmic
theta activity and spikes or sharp waves, mixed with 3–
4 Hz components of high amplitude, mainly in the occipital
regions (Boyd et al., 1988; Laan and Vein, 2005). The
delta rhythmicity is the most common EEG abnormality
(Vendrame et al., 2012) and it has recently been pro-
posed as a useful biomarker of both patient and mouse
models (Sidorov et al., 2017). Moreover, in patients with
15q11-13 deletions including the GABRB3, GABRA5,
GABRG3 genes encoding the diﬀerent subunits of the
GABAA receptor, the EEG disturbances were even stron-
ger (Frohlich et al., 2019).
EEG patterns in mice can be obtained by recording
resting-state local ﬁeld potentials (LFPs) in awake head-
ﬁxed mice (Buzsa´ki et al., 2012). Diﬀerent AS mouse
models including the Ube3a exon 5 deletion line and the
Floxed-STOP line showed EEG abnormalities that resem-
bled the changes in delta power (Jiang et al., 1998;
Judson et al., 2016; Born et al., 2017; Sidorov et al.,
2017). These changes in delta power are generalized
across the neocortex and has been attributed to the loss
of UBE3A speciﬁcally from GABAergic interneurons in the
brain (Judson et al., 2014; Sidorov et al., 2017).Sleep disturbances. Patients with AS have sleep
disturbances that include: decreased need for sleep,
changes in the sleep/wake cycle, early awakening and
general hyperactivity (Miura et al., 2002; Bruni et al.,
2004; Didden et al., 2004; Walz, 2007; Larson et al.,
2015). Moreover, EEG recordings of night time sleep sug-
gest that children with AS have reduced levels of REM
sleep and decreased sleep eﬃciency (Miano et al.,
2004) along with increased long-range EEG coherence
in the gamma band and fewer and shorter sleep spindles
(den Bakker et al., 2018).
Sleep changes can be assessed in mice by
investigating their activity in cages equipped with
running wheels and by obtaining EEG recordings during
the day/night cycle. Two studies evaluated the changes
in sleep – wake pattern resulting from loss of UBE3A
(Ehlen et al., 2015; Shi et al., 2015) using the Ube3a exon
5 deletion line (Jiang et al., 1998). Although both studies
point to changes in the sleep–wake architecture in AS
mice, Ehlen et al., 2015 showed that loss of UBE3A did
not alter circadian rhythmicity, but disrupted sleep home-
ostasis, while Shi et al., 2015 showed an altered circadian
period and phase, which can be further exacerbated by
manipulating the environmental light/dark conditions. ItPlease cite this article in press as: Rotaru DC et al. Angelman Syndrome: From Mouse Models to Therapy. Neurois thus important to continue investigating how UBE3A
aﬀects the sleep patterns in AS mice.A standardized test battery to reveal AS mouse
phenotypes
Robust behavioural phenotypes are crucial to identify
novel treatments, because they oﬀer suﬃcient power to
detect the eﬀect of the treatment, and minimize type I
errors (false eﬀectiveness of a drug). Recently the
Elgersma lab described a standardized behavioural test
battery which included the rotarod test, marble burying,
nest building, open ﬁeld, and forced swim test, all highly
useful for preclinical drug testing in AS (Sonzogni et al.,
2018). This study included a meta-analysis that integrated
eight independent experiments performed by ﬁve diﬀerent
experimenters, using 111 AS and 120 WT littermate mice
in the F1 hybrid 129S2-C57BL/6J background Fig. 3C.
This standardized behavioural test battery has now been
validated in six independently derived Ube3a lines: the
exon 5 deletion line, the PTC line, the conditional
Floxed-STOP line, the ﬂoxed exon 7 line, and the isoform
speciﬁc Ube3a Iso2 KO and Iso3 KO lines (Silva-Santos
et al., 2015; Sonzogni et al., 2018; Avagliano Trezza
et al., 2019) (Fig. 1).WHAT HAVE AS MOUSE MODELS TAUGHT US
ABOUT UBE3A FUNCTION?
Role of UBE3A in brain development and in the
mature brain (critical period)
In general, NDDs are caused by disrupted brain
maturation which results in dysfunction of motor, social,
cognitive and language function (Thapar et al., 2017).
Brain maturation is a relatively long process resulting from
complex interactions between genes and environment,
with crucial impact on the formation of diﬀerentiated neu-
rons, synapses and ultimately mature neuronal networks
(West and Greenberg, 2011). Full brain maturation
extends long after birth, during so called critical windows
when sensory experiences contribute signiﬁcantly to the
ﬁne-tuning of both local and long-range neuronal net-
works. It is thought that sensory input during critical win-
dows leads to speciﬁc gene expression patterns,
responsible for transforming sensory experience into
long-lasting changes at the level of synapses (Zhou
et al., 2008; Colonnese et al., 2010; Kuhlman et al.,
2013). Notably, during critical periods, neuronal circuits
are ﬂexible and thus able to be easily shaped by sensory
input (Innocenti and Price, 2005). Signiﬁcant impairment
often observed in NDDs, is the result of delayed or faster
closing of critical periods as well as improper translation of
the sensory input into long-lasting changes at synaptic
level leading to the formation of dysfunctional neuronal
networks (Niwa et al., 2010; Di Martino et al., 2011;
Forcelli et al., 2012; Biane et al., 2015; Peng et al.,
2016). Importantly, if the brain is not properly shaped dur-
ing these critical periods, the ability of the neuronal cir-
cuits to be modiﬁed during adulthood, is severely
reduced (Fig. 3A) (Hensch, 2004; Takesian and
Hensch, 2013).science (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
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models for AS, as a tool to investigate the role of
UBE3A in brain development and adult life, and to
explore the mechanisms underlying the critical periods.
The conditional Floxed-STOP mouse model allows
reinstatement of Ube3a gene expression at any desired
time throughout the animal life span, and hence can
provide insight into the role of UBE3A for brain
development (Silva-Santos et al., 2015). The investiga-
tors deﬁned the critical periods during which Ube3a gene
reactivation can ameliorate AS-like phenotypes. They
found that the window for improving motor coordination
extends furthest into postnatal development, whereas
the autism- and anxiety-related phenotypes appear to
be established much earlier and cannot be reversed by
adult Ube3a gene activation (Fig. 3B) (Silva-Santos
et al., 2015). It is important to mention that it is unclear
at what time point the critical period for these latter pheno-
types is precisely closed. Due to the challenge of tamox-
ifen administration to newborn pups during the perinatal
period, it is quite possible that the failure to adequately
rescue the marble burying and nest-building deﬁcits at
this age was at least in part, due to relatively inadequate
UBE3A reinstatement (Silva-Santos et al., 2015).
To study the role of UBE3A in the brain after initial
brain development, the conditional ﬂoxed exon 7 mouse
line has been used to delete Ube3a during diﬀerent
stages of life (Sonzogni et al., 2019). When Ube3a was
deleted in animals at 3 weeks or 12 weeks of age, no def-
icits were observed in motor coordination (rotarod), explo-
rative behaviour and anxiety (open ﬁeld), or repetitive
behaviour and anxiety (marble burying) Fig. 3D. Addition-
ally, the predisposition toward epilepsy was absent when
the gene was deleted after 3 weeks of age (Sonzogni
et al., 2019). The combined results obtained from these
inducible (Ube3a gene on or oﬀ) AS mouse models, indi-
cate that UBE3A predominantly plays an important role in
the perinatal period. An important caveat however, is that
none of these studies addressed the temporal require-
ment for restoring learning deﬁcits. As discussed above,
these phenotypes were too weak for detailed analysis.
But importantly, electrophysiological correction such as
hippocampal plasticity and excitability of neurons in the
prefrontal cortex could be achieved at any time during
and after brain development (Silva-Santos et al., 2015;
Rotaru et al., 2018).Fig. 3. Knowledge of critical periods is important for gene reactivation-bas
behavior. Innate behaviors are evident at birth such as the suckling reﬂex. Ho
reﬂexes, but that other behaviors that form the basis of our personality (inclu
trimester of pregnancy and the ﬁrst year of life. Sensory experiences have a
be acquired much longer, and there is no clear limit for higher cognitiv
reinstatement experiments in AS mice showed that marble burying, nest bu
upon gene reinstatement after three weeks, indicating that the critical period
time limit was observed for rescuing hippocampal plasticity or prefrontal cort
behavioral phenotypes in AS mice. A behavioral test battery consisting of rota
been developed and is now routinely used for screening drugs and addressin
AS mice (about n= 100 animals each) put together from 6 independent
experiments indicates that 7–15 mice (depending on the test) are nee
(Figure adapted from (Sonzogni et al., 2018). (D) Ube3a gene deletion expe
normal marble burying, nest building, open ﬁeld and rotarod behavior, w
throughout the entire life.
3
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UBE3A is expressed throughout the brain in both
glutamatergic and GABA-ergic neurons (Judson et al.,
2014, 2016; Rotaru et al., 2018) and loss of UBE3A leads
to synaptic and cellular changes in several brain areas. In
the last 10 years, AS mouse models have been used to
show that loss of UBE3A aﬀects layer 2/3 neurons of
the visual cortex (Wallace et al., 2012; Judson et al.,
2016), layer 5 pyramidal neurons and fast spiking
interneurons in prefrontal cortex (Rotaru et al., 2018), hip-
pocampal pyramidal neurons (Jiang et al., 1998; Van
Woerden et al., 2007; Kaphzan et al., 2011, 2013; Silva-
Santos et al., 2015), striatal medium spiny neurons
(Riday et al., 2012; Steinkellner et al., 2012;
Hayrapetyan et al., 2014), dopaminergic mesoaccumbal
terminals (Berrios et al., 2016), and neurons of medial
nucleus of the trapezoid body (MNTB) (Wang et al.,
2017). In the cerebellum, loss of UBE3A aﬀects cerebellar
Golgi cells (Egawa et al., 2012; Bruinsma et al., 2015).
Despite the high expression of UBE3A in cerebellar Purk-
inje cells, their function appears to be largely unaﬀected
by loss of UBE3A (Bruinsma et al., 2015).
Cellular dysfunction (electrophysiological
phenotype)
The increased excitability appears to be a common
feature across neuronal networks from AS mice
(Kaphzan et al., 2011; Wang et al., 2017; Rotaru et al.,
2018; Sidorov et al., 2018; Avagliano Trezza et al.,
2019). However, the exact underlying mechanisms
responsible for the hyperexcitable networks observed in
AS mice are unknown, and it is notable that loss of
UBE3A has a distinct impact on diﬀerent types of neurons
from diﬀerent areas of the brain. Since a hyper-excitable
circuit is often the result of an increased excitation to inhi-
bition ratio (Isaacson and Scanziani, 2011), we will dis-
cuss below the role of UBE3A in inhibitory and
excitatory synaptic transmission.
Changes in inhibitory synaptic transmission. Because
GABA-ergic interneurons regulate neocortical excitability
and seizure susceptibility, it is not surprising that GABA-
ergic deﬁcits have been implicated in the pathogenesis
of multiple NDDs (Le Magueresse and Monyer, 2013;
Wamsley and Fishell, 2017). In line with this, selectiveed therapy. (A) Critical periods have been well described for human
wever, it is evident that these innate behaviors are not just restricted to
ding social interactions) are also formed in the period between the last
critical period of several years (e.g. ocular dominance). Motor skills can
e learning. (Figure adapted from (Hensch, 2005). (B) Ube3a gene
ilding, forced swim-test and open ﬁeld deﬁcits cannot be fully rescued
closes before P21. Motor skill can be rescued up to 6 weeks, and no
ex function (ﬁgure adapted from (Silva-Santos et al., 2015). (C) Robust
rod, open ﬁeld, marble burying, forced swim test and nest building has
g mechanistic questions. The above experiments depict wild-type and
experiments of vehicle-treated animals. A power analysis of these
ded to have suﬃcient power for these tests (a= 0.05; b= 0.8).
riments in AS mice showed that UBE3A is not necessary after P21 for
hile the forced swim-test remains sensitive to Ube3a gene deletion
science (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
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like EEG abnormalities and enhances seizure susceptibil-
ity (Judson et al., 2016).
Several studies point to a decreased inhibitory
transmission in AS mice, which may be the result of
diﬀerent mechanisms. For example, Rotaru et al. (2018)
showed a decrease of inhibition in layer 5 of prefrontal
cortex (PFC) in AS mice possibly resulting from a
decreased activity of fast spiking interneurons, while other
studies show decreased inhibition in layer 2/3 pyramidal
neurons from visual cortex (Wallace et al., 2012), possibly
resulting from an increase of clathrin-coated vesicles in
presynaptic boutons. These ﬁndings may reﬂect diﬀer-
ences between visual cortex and PFC neurons as well
as layer speciﬁc diﬀerences. Alternatively, the diﬀerences
may result from using diﬀerent animal models, as the
decrease in the frequency of miniature inhibitory postsy-
naptic currents (mIPSCs) in the Ube3a exon 7 deletion
mice (Wallace et al., 2012), were not observed when
using the Floxed-STOP mouse model (Judson et al.,
2016). This eﬀect could possibly be due to minor tran-
scriptional read-through in Floxed-STOP mouse model,
resulting in slightly ‘‘leaky” Ube3a expression. If this is
the case, it could indicate that small amounts of UBE3A
are suﬃcient to prevent this deﬁcit.
Interestingly loss of UBE3A leads to decreased
excitability of fast spiking interneurons in layer 5 PFC
(Rotaru et al., 2018) and resembles the proﬁle of imma-
ture fast spiking neurons from PFC (Miyamae et al.,
2017), suggesting that these cells may fail to properly
mature (Stanurova et al., 2016). Although the precise
mechanism has to be demonstrated, Rotaru et al.
(2018) proposed a decrease via Nav1.1 subtype sodium
channels may lead to lower excitability of fast spiking
interneurons in AS mice (Yu et al., 2006; Ogiwara et al.,
2007; von Schoubye et al., 2018).
Yet, another mechanistically diﬀerent change in
inhibitory transmission in AS involves the GABA
transporter-1 (GAT1) which strongly regulates the level
of tonic inhibition (Farrant and Nusser, 2005; Bragina
et al., 2008), has been proposed as a potential UBE3A
substrate (Egawa et al., 2012). Dysfunction of this trans-
porter has been implied to cause changes in tonic inhibi-
tion of cerebellar Golgi cells and in GABA co-release from
dopaminergic mesoaccumbal terminals (Egawa et al.,
2012; Berrios et al., 2016).Changes in excitatory synaptic transmission. The
changes in excitatory transmission in AS mouse models
point to a more complex picture. Layer 5 pyramidal
neurons in PFC show an action-potential dependent
increase in the excitatory transmission (Rotaru et al.,
2018). In line with this, increased excitability of excitatory
neurons was observed in both PFC (Sidorov et al., 2018)
as well as hippocampus (Kaphzan et al., 2011, 2013).
Additionally, excitatory neurons in the hippocampus are
more excitable due to a decrease in spike threshold
(Kaphzan et al., 2011, 2013). Moreover, in vivo record-
ings from visual cortex pyramidal neurons showed
increased ﬁring rates of these cells (Wallace et al.,
2017). The increased excitability of pyramidal neuronsPlease cite this article in press as: Rotaru DC et al. Angelman Syndrome: From Mouse Models to Therapy. Neufrom layer 5 prefrontal cortex may be the result of
changes in Kv1 channels. Kv1 channels are highly
expressed at the axon initial segment (AIS) (Inda et al.,
2006; Kole et al., 2007; Van Wart et al., 2007), a sub-
region of the axon shown to be enlarged in AS mouse
models and potentially responsible for increased excitabil-
ity of neurons in the hippocampus (Kaphzan et al., 2011,
2013) and the medial nucleus of the trapezoid body
(MNTB) (Wang et al., 2017).
In addition to the changes observed in the
electrophysiological properties of excitatory neurons,
many studies point to a decreased spine density in the
visual cortex, cerebellum, and hippocampus of the
deletion exon 5 mouse model (Dindot et al., 2008;
Yashiro et al., 2009; Sato and Stryker, 2010; Kim et al.,
2016; Sun et al., 2016). A decreased spine density would
tend to result in a decreased excitatory transmission,
which may be the results of homeostatic compensatory
mechanism triggered by the increased AP ﬁring rates
(Keck et al., 2017). Hence, it remains a question which
are the primary versus the compensatory electrophysio-
logical changes in AS. New experiments need to focus
on identifying the time points during development when
each deﬁcit appears, followed by deﬁcit speciﬁc treat-
ment. Such approaches will disentangle the primary and
secondary (homeostatic) deﬁcits.
UBE3A targets that could be responsible for the
neuronal deﬁcits
The UBE3A protein functions as an E3 ubiquitin ligase by
attaching ubiquitin moieties to its protein targets, labelling
them for destruction, altered localisation or impacting their
function. Although many targets have been put forward,
there are a couple of targets of speciﬁc interest due to
their critical role in neuronal function. For instance,
direct interactions have been reported between UBE3A
the SK2 channel (a regulator of excitability; Sun et al.,
2015), the GABA (GAT1) transporter (a regulator of inhi-
bitory transmission; Egawa et al., 2012), the RhoA gua-
nine nucleotide exchange factor Ephexin5 (responsible
for regulating excitatory synapse formation; Margolis
et al., 2010) and ARC (a regulator of excitatory transmis-
sion; Greer et al., 2010; Smith et al., 2011, Pastuzyn and
Shepherd, 2017). However, the ﬁnding that ARC is a sub-
strate has more recently been retracted (Mandel-Brehm
et al., 2015), and it has been suggested that ARC levels
may be regulated at the transcriptional level instead
(Kuhnle et al., 2013). Loss of UBE3A also (indirectly)
aﬀects CAMK2 activity, an important regulator of neuronal
plasticity (Weeber et al., 2003; Van Woerden et al., 2007).
For many of these possible targets is it is unclear
whether they are bona fide UBE3A substrates. This can
only be assessed with well-controlled ubiquitination
assays. Since loss of UBE3A has a strong impact on
the neurons, it often remains unclear whether changes
in protein levels of a presumed target, are truly the
result of decreased ubiquitination by UBE3A. It is also
noteworthy that UBE3A interacts with the proteasome
and may regulate proteostasis in a much broader way,
thereby aﬀecting many critical proteins without actually
being targets (Martı´nez-Noe¨l et al., 2012; Lee et al.,roscience (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
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2019). Hence, proteins with a high turn-over such as for
instance proteins of the b-catenin/ Wnt signalling path-
way, an important pathway in neurodevelopment, may
be aﬀected indirectly by changes in UBE3A activity (Yi
et al., 2017; Ku¨hnle et al., 2018; Lopez et al., 2019).The role of UBE3A isoforms
Searches for protein interactors of UBE3A identiﬁed
protein interactors/targets of UBE3A that are located in
nucleus, cytoplasm or synapse (reviewed in (Lopez
et al., 2019)). In the mouse brain, two UBE3A protein iso-
forms are expressed as a result of alternative splicing; the
cytoplasmic (long) isoform (Iso2) and the nuclear (short)
isoform (Iso3) which diﬀer only by a 21 amino acid stretch
at the amino terminus of UBE3A (Miao et al., 2013;
Avagliano Trezza et al., 2019). Although it has been
reported that the non-coding (truncated) Ube3a transcript
(Iso1) plays a role in dendrite growth (Valluy et al., 2015)
the relevance for AS was questioned by a recent study
(Avagliano Trezza et al., 2019), and the transcript has
recently been retracted from the NCBI database.
There is broad consensus on the predominantly
nuclear localization of UBE3A in murine derived neurons
(Dindot et al., 2008; Burette et al., 2017). Quantiﬁcation
of UBE3A bands on Western blots has determined the
ratio of the mouse cytoplasmic UBE3A Iso2 to the mouse
nuclear Iso3 protein to be 20%:80% hinting at a potentially
strong nuclear role for UBE3A (Avagliano Trezza et al.,
2019). This notion was strengthened by data from the
same study in which behavioural experiments using
isoform-speciﬁc Ube3a mouse models clearly showed
that mice lacking the nuclear isoform were showing the
AS mouse phenotypes, while those lacking the cytoplas-
mic isoform were indistinguishable from WT littermates.
UBE3A also displays a predominantly nuclear localization
in human neurons as well (Burette et al., 2017; Avagliano
Trezza et al., 2019). Unlike its murine counterpart, human
UBE3A consists of 3 protein isoforms diﬀering only at their
N-terminal end (Yamamoto et al., 1997). Interestingly a
mutation that speciﬁcally abrogates the expression of
the predominantly nuclear (short) human UBE3A isoform
1 (homologous to mouse Iso3) has recently been identi-
ﬁed in AS patients (Sadhwani et al., 2018). Together with
the ﬁnding that some AS associated missense mutations
in UBE3A interfere with nuclear targeting (Avagliano
Trezza et al., 2019), these ﬁndings further strengthen
the point that UBE3A acts predominantly in the nucleus.
However, it is important to note that despite the fact that
most UBE3A protein is found in the nucleus, both mouse
and human cells also express cytoplasmic forms of
UBE3A, indicating that there likely is a cytoplasmic func-
tion for UBE3A as well.
Although the ﬁndings described above seem to point
in the direction of a primarily nuclear role for UBE3A,
the role of UBE3A in the nucleus is unknown. UBE3A
has been shown to bind to and act as a coactivator to a
number of steroid hormone receptors aﬀecting the
transcriptional activity of the nuclear receptor targets,
although this has been found to be independent ofPlease cite this article in press as: Rotaru DC et al. Angelman Syndrome: From Mouse Models to Therapy. Neuroubiquitin ligase activity (Nawaz et al., 1999), and the rele-
vance to AS is unclear.
Using the AS mouse model to identify a therapy for
AS
Currently, only symptomatic treatments are available for
AS, which aim at reducing seizures, improving sleep or
improve behavioural aspects (Tan and Bird, 2015). Pre-
clinical studies using AS mouse models are not only cru-
cial in the identiﬁcation of drug targets but also provide
important information about the therapeutic dose, optimal
age of treatment, and the best outcome measures to be
used in a clinical trial. In particular, the motor deﬁcits, sei-
zure susceptibility, sleep deﬁcits EEG anomalies, and
some of the behavioural deﬁcits provide good transla-
tional value.
Treatment strategies tested in AS mouse models are
often aimed at targeting the identiﬁed pathophysiological
mechanisms (van Woerden et al., 2007; Egawa et al.,
2012; Kaphzan et al., 2013; Sun et al., 2015). More
recently, a very promising therapy for AS has been
described, which involves restoring UBE3A levels. This
was achieved by reactivating the intact, but silenced
paternal copy of the Ube3a gene (Huang et al., 2012;
Meng et al., 2013). But regardless of the therapeutic
choice, it is essential to determine the critical time window
during which appropriate intervention can overcome the
neurodevelopmental deﬁcits associated with AS (Silva-
Santos et al., 2015).
Pathophysiological and molecular mechanisms as
targets for treatment. The observed decrease in
hippocampal long term potentiation (LTP) in AS mice
(Jiang et al., 1998) prompted further research into the role
of calcium/calmodulin-dependent protein kinase II
(CaMK2) (Weeber et al., 2003). Thus, one of the ﬁrst
molecular dysfunctions identiﬁed in AS mice was the
decreased CAMK2 activity via an increased inhibitory
phosphorylation at the CAMK2 Thr305 and Thr306 sites
(Weeber et al., 2003). Genetically reducing CAMK2 inhibi-
tory phosphorylation was suﬃcient to rescue both the LTP
deﬁcits and the (motor) learning deﬁcits and seizures (van
Woerden et al., 2007), but unfortunately, drugs that can
mimic this eﬀect have not yet been identiﬁed.
Analysis of the electrophysiological properties of
hippocampal neurons in AS mice revealed that CA1
pyramidal neurons are more excitable due to altered
passive and active intrinsic membrane properties
(Kaphzan et al., 2011). These changes were correlated
with the increased expression of the a1 subunit of Na/K
ATPase (a1-NaKA), as well as increased AIS length
(Kaphzan et al., 2011). When a1-NaKA was reduced in
AS mice the increased excitability and AIS length were
rescued along with a rescue of the impaired LTP and
hippocampus-dependent memory deﬁcits (Kaphzan
et al., 2013).
Another electrophysiological change observed in
hippocampal neurons of AS mice is an increased in the
levels of small-conductance calcium-activated potassium
channels (SK channels) (Sun et al., 2015). When the cur-
rents through these channel were blocked by treatmentscience (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
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(Sun et al., 2015).
Recently, two unsuccessful clinical trials aiming to
treat the motor deﬁcits (Levodopa trial register
NCT01281475) and cognitive impairments (Minocycline
trial register NCT01531582 and NCT02056665), have
been performed. The Levodopa trail is based on the
observation that levodopa treatment results in reduced
inhibitory phosphorylation of CAMK2 Thr305/6 (Brown
et al., 2005), a site shown to be hyper-phosphorylated in
AS mice (Weeber et al., 2003; van Woerden et al.,
2007). Moreover, it has been suggested that decreased
CAMK2 activity leads to decreased striatal dopamine
transporter function in AS mice (Steinkellner et al.,
2012), a brain area also involved in motor function.
Indeed, Levodopa (Tan and Bird, 2015) and Minocycline
(Grieco et al., 2014) improved motor function in AS mice.
However, more recently these drugs were retested in a
study that was better powered and included a number of
additional behavioural tests. No signiﬁcant eﬀects of
Levodopa or Minocycline on any of the tests were
observed (Sonzogni et al., 2018). These ﬁndings empha-
size the need to rigorously test potential treatments in AS
mouse models using robust assays and suﬃciently pow-
ered cohorts, before the drugs can be tested in the clinic.
The pronounced motor dysfunction associated with
the loss of UBE3A, has been an important driver to
investigate cerebellar function, a brain area important
for normal motor function (Middleton, 2000). Two studies
showed decreased tonic inhibition on cerebellar granule
neurons (Egawa et al., 2012; Bruinsma et al., 2015).
Pharmacological treatment of AS mice with an extra-
synaptic GABAA receptor–selective agonist, THIP/
Gaboxadol, which has been previously shown to increase
the levels of tonic inhibition (Brown et al., 2002), resulted
in a partial rescue of the motor dysfunction (Egawa et al.,
2012). Possibly, this partial rescue is due to the ﬁnding
that gross motor dysfunction of AS mice does not seem
to originate from the cerebellum (Egawa et al., 2012;
Bruinsma et al., 2015). Gaboxadol is currently being
tested in individuals with AS (NCT0299630,
NCT04106557).
Gene reactivation. Since the absence of functional
UBE3A is the common denominator in all AS cases,
reinstating UBE3A protein expression in AS neurons is
an attractive treatment strategy to pursue.
One approach to bring back UBE3A protein is through
ectopically expressed UBE3A. This has been achieved by
the introduction of the dominant short form of Ube3a
cDNA (mouse Iso 3) through AAV viral mediated gene
therapy in AS mice. Although the mouse experiments
were statistically underpowered, the authors described a
partial rescue of synaptic plasticity (LTP) and water
maze phenotypes, and a full rescue of the fear
conditioning deﬁcit (Daily et al., 2011). No rescue was
observed on the rotarod motor coordination task, which
is likely caused by the fact that the AAV injections were
limited to hippocampus. Although potentially very promis-
ing, the AAV viral approach does bring along some obsta-
cles. The level of UBE3A protein is tightly regulated inPlease cite this article in press as: Rotaru DC et al. Angelman Syndrome: From Mouse Models to Therapy. Neubrain and too much UBE3A may result in an ASD pheno-
type (Elgersma, 2015) although little is known about the
eﬀect of increased post-natal levels of UBE3A protein.
The viral approach, besides it being irreversible, lacks
the ability to control the number of viral particles entering
each cell, and as a consequence, there is little control
over protein levels in individual cells. Also, there will be
the need to take into consideration that in human neurons,
three UBE3A protein isoforms are expressed and their
individual impact on the normal functioning of neurons
has not yet been elucidated.
As mentioned earlier, the paternal UBE3A allele is
silenced by the UBE3A-ATS RNA transcript and the
reactivation of the silent paternal UBE3A gene can be
achieved by targeting the UBE3A-ATS transcript. A
major advantage of targeting the UBE3A-ATS transcript
to reactivate the dormant paternal UBE3A allele,
although necessitating repetitive life-long treatment, is
that it will not lead to an excessive amount of UBE3A in
neurons. Two research groups initiated this line of
research and have used mouse models to determine
the eﬃcacy of Topoisomerase I inhibitors (Huang et al.,
2012; Lee et al., 2018) and anti-sense oligonucleotides
(ASOs) to reactivate the paternal Ube3a allele (Meng
et al., 2015). Topoisomerase I inhibitors were identiﬁed
through a high throughput small molecule screen carried
out using primary neurons derived from mice expressing
paternal Ube3a-YFP (Huang et al., 2012). Huang and col-
leagues were able to show that treating neurons with
Topoisomerase I inhibitors such as Topotecan and
Indotecan resulted in the reduction of Ube3a-ATS tran-
scription and a concomitant increase of paternally
expressed UBE3A protein (Huang et al., 2012; Lee
et al., 2018).
In parallel, the Beaudet lab in collaboration with Ionis
Pharmaceuticals, Inc., showed that ASOs can target the
Ube3a-ATS and activate paternal Ube3a transcription
(Meng et al., 2015). ASOs are chemically modiﬁed
oligonucleotides; a chimeric molecule consisting of a cen-
tral stretch of DNA ﬂanked by ribonucleotides that are able
to hybridise with and breakdown a nuclear target RNA in
an RNAse H dependant manner (Crooke et al., 2018).
By administering ASOs via a single intracerebroventricular
(ICV) injection into adult mice, Meng and colleagues tar-
geted the neuronal Ube3a-ATS RNA and reactivated the
paternalUbe3a allele for up to 4 months, rescuing the con-
textual fear conditioning phenotype in their cohort of adult
AS mice (Meng et al., 2015). However, as discussed
above, this phenotype is not very robust in AS mice. More-
over, the investigators were not able to rescue other AS
related behavioural phenotypes such as the open ﬁeld,
marble burying and accelerating rotarod tests. The exper-
iments with the inducible Flox-STOP mouse model, in
which the Ube3a gene was switched on at speciﬁc times
in development, suggests that the failure to observe a
behavioural rescue by ASO induced UBE3A re-
expression, is likely due to the fact that the treated mice
were adults (Silva-Santos et al., 2015). This last ﬁnding
emphasises the importance of animal models in biomedi-
cal research, as the critical window for treatment of AS
could not have been probed using cell lines.roscience (2020), https://doi.org/10.1016/j.neuroscience.2020.02.017
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ASO-mediated reinstatement of UBE3A have been
proposed in literature, such as the zinc-ﬁnger, TALEN or
CRISPR based artiﬁcial transcriptional modulators, but
feasibility of such approaches have yet to be
demonstrated (Bailus et al., 2016).AS mouse models: future directions
There are a few major areas in which mouse models may
shed further light on AS pathophysiology:
1) Loss of UBE3A aﬀects a multitude of pathways (re-
viewed in Lopez et al 2019B). The role of the cyto-
plasmic and in particular nuclear UBE3A in the
pathophysiology of AS is still unclear will be a focus
for more research. In addition, the role of UBE3A in
regulating proteasome activity should be
investigated.
2) An important limitation of the Ube3a re-activation
approach, is the limited therapeutic window in which
such a therapy appears to be eﬀective. What dic-
tates this limited critical period for behavioural res-
cue? Can it be extended by pharmacological
means? And why can epilepsy in adult mice eﬃ-
ciently be treated with anti-epileptic drugs but is
Ube3a gene reinstatement not eﬀective in adult ani-
mals? (Silva-Santos et al., 2015). Further studies
using the inducible AS mouse model should provide
insight into these mechanisms.
3) Although UBE3A is associated with several pheno-
types, we do not have a good understanding of
which brain areas underlie these deﬁcits. Ube3a
conditional mice can help us to identify the underly-
ing brain areas. This will also help us identify the
cellular (electrophysiological) correlates for these
behavioural deﬁcits.
4) Although it is clear that complete loss of (maternal)
UBE3A expression results in AS, how much UBE3A
protein is actually needed to sustain normal devel-
opment and brain function. And to what extent is
bi-allelic UBE3A expression during pre-natal devel-
opment needed? And what are the roles of each of
the 3 isoforms in this process? These are important
questions for gene reinstatement strategies.
5) The inclusion of large-deletion AS mouse models,
such as those described by Gabriel et al. (1999)
and Jiang et al. (2010), to help determine the role
of all genes that are part of the large deletion in
the majority of AS patients.ACKNOWLEDGEMENTS
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